Literature DB >> 10204782

Heart involvement in muscular dystrophies due to sarcoglycan gene mutations.

P Melacini1, M Fanin, D J Duggan, M P Freda, A Berardinelli, G A Danieli, A Barchitta, E P Hoffman, S Dalla Volta, C Angelini.   

Abstract

Mutations in the sarcoglycan genes cause autosomal-recessive muscular dystrophies. Because sarcoglycan genes and their protein products are highly expressed both in skeletal and cardiac muscle, patients with these mutations might be expected to be at risk to develop dilated cardiomyopathy. We therefore studied 13 patients with alpha-, beta-, gamma-sarcoglycan gene mutations by thorough cardiological assessment. Electrocardiographic or echocardiographic abnormalities were observed in about 30% of cases showing a severe course of muscular dystrophy. No correlation was found between the presence of cardiac abnormalities and the type of mutation or sarcoglycan gene involved. The cardiac involvement was never severe, but it may be detected in early stages of the muscle disease. The absence of overt cardiac dysfunction may be due to lower sarcoglycan protein expression in cardiac than skeletal muscle or to less sarcolemmal instability at the myocardial level, possibly related to the different distribution of forces generated by contraction of the myocardium with respect to proximal limb-girdle muscles.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10204782     DOI: 10.1002/(sici)1097-4598(199904)22:4<473::aid-mus8>3.0.co;2-5

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  22 in total

1.  Occult left ventricular dysfunction diagnosed by myocardial performance index in patients with limb girdle muscle dystrophy: A case control study.

Authors:  Rajashekar R Gurrala; Venkata Mb Alla; Wilbert S Aronow; Jai S Shankar; Meena K Angamutta; Krishna Lanka; Sundaram Challa; Chandra K Nair
Journal:  Int J Angiol       Date:  2007

2.  Sarcoglycan, the heart, and skeletal muscles: new treatment, old drug?

Authors:  J A Towbin; N E Bowles
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

3.  Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophy.

Authors:  Saurabh Dahiya; Srikanth Givvimani; Shephali Bhatnagar; Natia Qipshidze; Suresh C Tyagi; Ashok Kumar
Journal:  J Immunol       Date:  2011-08-01       Impact factor: 5.422

4.  Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex.

Authors:  R D Cohn; M Durbeej; S A Moore; R Coral-Vazquez; S Prouty; K P Campbell
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

5.  Systemic AAV-Mediated β-Sarcoglycan Delivery Targeting Cardiac and Skeletal Muscle Ameliorates Histological and Functional Deficits in LGMD2E Mice.

Authors:  Eric R Pozsgai; Danielle A Griffin; Kristin N Heller; Jerry R Mendell; Louise R Rodino-Klapac
Journal:  Mol Ther       Date:  2017-03-09       Impact factor: 11.454

Review 6.  The genetic and molecular basis of muscular dystrophy: roles of cell-matrix linkage in the pathogenesis.

Authors:  Motoi Kanagawa; Tatsushi Toda
Journal:  J Hum Genet       Date:  2006-09-13       Impact factor: 3.172

7.  Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy.

Authors:  S Tsubata; K R Bowles; M Vatta; C Zintz; J Titus; L Muhonen; N E Bowles; J A Towbin
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

Review 8.  Mendelian forms of structural cardiovascular disease.

Authors:  Calum A MacRae
Journal:  Curr Cardiol Rep       Date:  2013-10       Impact factor: 2.931

Review 9.  [Limb girdle muscular dystrophies].

Authors:  J Finsterer
Journal:  Nervenarzt       Date:  2004-12       Impact factor: 1.214

10.  β-Sarcoglycan gene transfer decreases fibrosis and restores force in LGMD2E mice.

Authors:  E R Pozsgai; D A Griffin; K N Heller; J R Mendell; L R Rodino-Klapac
Journal:  Gene Ther       Date:  2015-08-20       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.